news

CUPERTINO, Calif., Jan. 6, 2022 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022. Presentation details are as follows: H.C. […]

– DURECT to receive near-term upfront cash payments totaling $6 million, potential additional milestone payments of up to $130 million and tiered low to mid double-digit royalties based on U.S. sales – Innocoll granted exclusive development and commercialization rights to POSIMIR in the United States – DURECT to discuss agreement on Conference Call and Webcast

CUPERTINO, Calif., Dec. 14, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience. “We are delighted to welcome Peter García to our board of directors as we continue to advance our

CUPERTINO, Calif., Nov. 29, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5th Annual NASH Summit being held virtually from today through December 2, 2021.  Our President and Chief Executive Officer, James E. Brown, D.V.M. will join hepatology experts in a session to discuss key drivers of morbidity and

AH hospitalizations increased by approximately 4.8% per year between 2015 and 2018 Approximately 80% of AH patients who died while hospitalized had acute kidney failure CUPERTINO, Calif., Nov. 12, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the presentation of data at the American Association for The Study of Liver Diseases (AASLD) The Liver

CUPERTINO, Calif., Nov. 10, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients. “AH is a global condition and we are excited to

CUPERTINO, Calif., Nov. 8, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D. will present a poster at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting® 2021 to be held virtually November 12-15, 2021.  The E-Poster will provide data on recent prevalence, co-morbidities, and mortality in hospitalized alcohol-associated hepatitis

-Earnings Call and Webcast Today, November 2nd at 4:30 p.m. ET -Expanded number of AHFIRM study sites -Opened first ex-US AHFIRM study sites -Advanced POSIMIR licensing process CUPERTINO, Calif., Nov. 2, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2021 and provided a corporate update. “I

CUPERTINO, Calif., Oct. 26, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the market close on Tuesday, November 2, 2021.     Tuesday, November 2 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time Toll Free:  877-869-3847 International:                    201-689-8261 Conference ID:     13724352

CUPERTINO, Calif., Oct. 7, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of Equity